Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
LL-37 (LL37) is a immune peptide, at the preclinical stage in the published literature. Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial activity and immunomodulatory effects.
Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial activity and immunomodulatory effects.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-200 mcg |
Direct antimicrobial action, immune cell activation, wound healing promotion.
Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial activity and immunomodulatory effects.
Direct antimicrobial action, immune cell activation, wound healing promotion.
LL-37 is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.